Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug871 | Convalescent Plasma as Therapy for Covid-19 patients Wiki | 0.38 |
drug2690 | Questionnaire collection Wiki | 0.38 |
drug2954 | Saliva specimen Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3928 | oropharyngeal swabs Wiki | 0.38 |
drug2952 | Saliva sample Wiki | 0.38 |
drug2748 | Rapid detection test Wiki | 0.38 |
drug2295 | Optional questionnaire completion Wiki | 0.38 |
drug1283 | Fingerstick Wiki | 0.38 |
drug2106 | Nasal Swab Wiki | 0.38 |
drug2642 | Psychological and Behaviour Change Support Wiki | 0.38 |
drug2294 | Optional blood completion Wiki | 0.38 |
drug2226 | Nutrition Wiki | 0.38 |
drug3184 | Stool collection Wiki | 0.38 |
drug2195 | Non-contact ECG Wiki | 0.38 |
drug3357 | Throat swab Wiki | 0.27 |
drug1831 | Low Dose Radiotherapy Wiki | 0.27 |
drug502 | Breath Biopsy face masks with removable filters and fitted PVA strip Wiki | 0.27 |
drug3031 | Serum testing Wiki | 0.27 |
drug1201 | Exercise Wiki | 0.27 |
drug2600 | Probiotic Wiki | 0.22 |
drug359 | BCG vaccine Wiki | 0.19 |
drug969 | Data collection Wiki | 0.17 |
drug2448 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D011565 | Psoriasis NIH | 0.22 |
D003327 | Coronary Disease NIH | 0.19 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D006331 | Heart Diseases NIH | 0.14 |
D008173 | Lung Diseases, Obstructive NIH | 0.14 |
D001172 | Arthritis, Rheumatoid NIH | 0.11 |
D001168 | Arthritis NIH | 0.10 |
D007239 | Infection NIH | 0.09 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.08 |
D018352 | Coronavirus Infections NIH | 0.07 |
D003141 | Communicable Diseases NIH | 0.05 |
D014777 | Virus Diseases NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003765 | Psoriasiform dermatitis HPO | 0.22 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.15 |
HP:0006536 | Pulmonary obstruction HPO | 0.14 |
Navigate: Correlations HPO
There are 7 clinical trials
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
According to epidemiological models, the seroprevalence of SARS-CoV-2 infection in Île-de-France as of 11 May was between 10 and 15%. Preliminary data on the number of professionals evicted from nurseries on suspicion of COVID-19 (on clinical grounds) seem to be of the same order of magnitude, but need to be confirmed by a biological technique. Children would be susceptible to infection but often asymptomatic.
Description: Proportion of children with a positive rapid serological test (presence of anti-SARS-CoV2 antibodies (IgM or IgG)).
Measure: Assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period Time: Day of intervention (1 day)The primary aim of this study is to investigate the performance of Breath Biopsy RD for the detection of SARS-CoV-2 in both a clinical and at home setting.
Description: The purpose of this stage is to confirm the optimal extraction protocol to detect the presence of SARS-CoV-2 from the aerosols captured in the Breath Biopsy RD device. Up to two Breath Biopsy RD sample will be collected alongside a nasopharyngeal. The swab obtained during this stage is to be analysed in parallel to the extracted breath aerosols in the lab of the lab and will be used as a positive control.
Measure: Positive control for technical validation Time: 1 yearDescription: The aim is to assess the test performance of the Breath Biopsy RD devices in a real live clinical setting. Subjects with a high clinical suspicion of nCOVID-19 based on clinical triage will be requested to participate. A single Breath Biopsy RD collector will be collected in parallel with the standard diagnostic work-up consisting of a CT-scan and a nasopharyngeal swab.
Measure: Evaluation of test performance Time: 1 yearDescription: The aim of the final outcome is to evaluate the performance and acceptability of using the Breath Biopsy RD as an at home test for identification of the presence of SARS-CoV-2. The OLVG phone application used for triage of the presence of nCOVID-19 will be used to identify subjects at the highest risk of having nCOVID-19. These subjects will be sent a Breath Biopsy RD collector and oropharyngeal swab for at home testing. Any subject who has a positive Breath Biopsy test for SARS-CoV-2 will be contacted and advised to receive a nasopharyngeal test for assessment of viral presence. Both tests will be self-administered to mimic an at home use scenario. The performance of both tests will be confirmed from the perspective of 1. Adherence 2. Subject comfort 3. Number of SARS-CoV-2 positive cases.
Measure: Evaluation of at home test Time: 1 yearPerformance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
Description: Evaluation of performance of the device versus a reference method using standard qualitative comparison techniques (Percent Agreement)
Measure: Performance Evaluation Time: 4 monthsRecent studies have shown that some individuals may be asymptomatic but continue to shed the COVID-19 virus. These individuals may represent a population that can unknowingly transmit the virus. Healthcare workers (HCW) may acquire COVID-19 from the community or from possibly infected patients. It is important to gather data with respect to this to further understand the prevalence of asymptomatic carriage in individuals who work in research facilities, offices and clinical areas of hospitals and research facilities/institutes since this has important implications for infection control, as well as staff and patient safety. The purpose of this study is to test whether a proportion of these individuals may be asymptomatic shedders of the COVID-19 virus.
The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).
Description: RT-PCR on nasopharyngeal is considered as gold standard
Measure: Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus Time: At diagnosisDescription: Number of samples tested in a day for each test
Measure: Practicability to samples Time: At diagnosisDescription: Quantity of premises required for each test
Measure: Practicability to premises Time: At diagnosisDescription: Feasibly Reading and interpretation For each test
Measure: Practicability to interpretation Time: At diagnosisDescription: Render times for each test
Measure: Practicability to render time Time: At diagnosisDescription: Research of IgG by ELISA and RDT
Measure: IgG Antibody detection in saliva Time: At diagnosisDescription: Research of IgM by ELISA and RDT
Measure: IgM Antibody detection in saliva Time: At diagnosisDescription: Research of IgA by ELISA and RDT
Measure: IgA Antibody detection in saliva Time: At diagnosisDescription: Evaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)
Measure: Patient tolerance of the salivary self-sampling Time: At diagnosisDescription: Evaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)
Measure: Operator tolerance of the salivary self-sampling Time: At diagnosisDescription: Including sampling, transport, technique (consumables, reagents, machine), human resources
Measure: Cost of each approach Time: At diagnosisThe main objectives of this study are 1. to establish the prevalence of SARS-CoV-2 in schools and kindergartens in the State of Mecklenburg-Vorpommern in autumn and winter 2020/2021 2. to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in teachers and childcare educators over time
Description: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 5 monthsDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: At study inclusionDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: 5 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: At study inclusionDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 1 monthDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 2 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 3 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 4 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 5 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: At study inclusionDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 1 monthDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 2 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 3 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports